1. De Kouchkovsky I, Abdul-Hay M. ‘Acute myeloid leukemia: A comprehensive review and 2016 update.’ Blood Cancer Journal. 2016; 6(7): 2016.
2. Murati A, Brecqueville M, Devillier R, Mozziconacci MJ, Gelsi-Boyer V, Birnbaum D. Myeloid malignancies: Mutations, models and management. BMC Cancer. 2012;12.
3. Tang L, Zhang Y, Hu Y, Mei H. Hematological Malignancies. 2021; Disponible en: https://doi.org/10.1155/2021/6616391
4. Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020; 367(6481).
5. Kantarjian H, Kadia T, Dinardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41. Disponible en: https://doi.org/10.1038/s41408-021-00425-3
6. Ferguson P, Craddock C. Allogeneic transplantation in primary refractory AML. Bone Marrow Transplant. 2017;52(7):950–1. Disponible en: http://dx.doi.org/10.1038/bmt.2017.61
7. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340–52.
8. Döhner, H, Weisdorf, DJ, Bloomfield CD (2015). Acute Myeloid Leukemia. N Engl J Med. 2015; 373(12):1136–1152.
9. Pei X, Huang X. New approaches in allogenic transplantation in AML. Semin Hematol. 2019; 56(2):147–54. Disponible en https://doi.org/10.1053/j.seminhematol.2018.08.007
10. Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, et al. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 2018;173(6):1439-1453.e19.
11. Kenderian S, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette J, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015; 29(8): 1637-47. Disponible en: www.nature.com/leu
12. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591–619.
13. Guerriero JL. Macrophages: Their Untold Story in T Cell Activation and Function. International Review of Cell and Molecular Biology. 2019 342: 73–93. Disponible en: https://doi.org/10.1016/bs.ircmb.2018.07.001
14. Saline M, Rödström KEJ, Fischer G, Orekhov VY, Karlsson BG, Lindkvist-Petersson K. The structure of superantigen complexed with TCR and MHC reveals novel insights into superantigenic T cell activation. Nat Commun. 2010;1(8).
15. Piepenbrink KH, Blevins SJ, Scott DR, Baker BM. The basis for limited specificity and MHC restriction in a T cell receptor interface. Nat Commun. 2013;4:1–9.
16. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci. 1989;86(24):10024–8.
17. Almåsbak H, Aarvak T, Vemuri MC. CAR T Cell Therapy: A Game Changer in Cancer Treatment. J Immunol Res. 2016; 2016.
18. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014; 257 (1): 56-71.
19. Larson RC, Maus M V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145–61. Disponible en: http://dx.doi.org/10.1038/s41568-020-00323-z
20. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4). Disponible en: http://dx.doi.org/10.1038/s41408-021-00459-7
21. Malissen B. CAR T cells: from tinkering to rational design. Cell Res. 2020;30(11):948–9. Disponible en: http://dx.doi.org/10.1038/s41422-020-00420-6
22. Srivastava S, Riddell SR. Engineering CAR-T cells: Design concepts. Trends Immunol. 2015; 36(8):494–502. Disponible en: http://dx.doi.org/10.1016/j.it.2015.06.004
23. Xu D, Jin G, Chai D, Zhou X, Gu W, Chong Y, et al. The development of CAR design for tumor CAR-T cell therapy. Oncotarget. 2018;9(17):13991–4004.
24. Caldwell KJ, Gottschalk S, Talleur AC. Allogeneic CAR Cell Therapy—More Than a Pipe Dream. Front Immunol. 2021;11(January):1–12.
25. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377(26):2531–44.
26. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439–48.
27. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019; 380(18):1726–37.
28. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331–42.
29. Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020;38(32):3794–804.
30. Hay AE, Cheung MC. CAR T-cells: costs, comparisons, and commentary. J Med Econ. 2019;22(7):613–5. Disponible en: http://dx.doi.org/10.1080/13696998.2019.1582059
31. Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care among Patients with Relapsed or Refractory Large B-Cell Lymphoma. JAMA. 2020;3(4):1–14.
32. Thommen DS, Schumacher TN. T Cell Dysfunction in Cancer. Cancer Cell. 2018;33(4):547–62. Disponible en: https://doi.org/10.1016/j.ccell.2018.03.012
33. Köhl U, Arsenieva S, Holzinger A, Abken H. CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications. Hum Gene Ther. 2018;29(5):559–68.
34. Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185–99. Disponible en: http://dx.doi.org/10.1038/s41573-019-0051-2
35. Paolo Tambaro F, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, et al. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia. 2021; 35(11): 3282-86. Disponible en: https://doi.org/10.1038/s41375-021-01232-2
36. Wang Q, Wang Y, Lv H, Han Q, Fan H, Guo B, et al. Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia. Mol Ther. 2014;23:184–91. Disponible en: www.moleculartherapy.org
37. Marcus A, Eshhar Z. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Expert Opin Biol Ther. 2014;14(7):947–54.
38. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23(9):2255–66.
39. Graham C, Jozwik A, Pepper A, Benjamin R. Allogeneic car-t cells: More than ease of access? Cells. 2018;7(10):1-11.
40. Li C, Mei H, Hu Y. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. Brief Funct Genomics. 2020;19(3):175–82.
41. Scholefield J, Harrison PT. Prime editing – an update on the field. Gene Ther. 2021;28(7–8):396–401.
42. Qasim W. Allogeneic CAR T cell therapies for leukemia. Am J Hematol. 2019 ;94(S1):S50–4. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25399
43. Kamiya T, Wong D, Png YT, Campana D. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Adv. 2018;2(5):517–28.
44. Liu X, Zhao Y. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy. Curr Res Transl Med. 2018;66(2):39–42. Disponible en: https://doi.org/10.1016/j.retram.2018.04.003
45. Ren J, Zhang X, Liu X, Fang C, Jiang S, June CH, et al. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 2017;8(10):17002–11.
46. Bhatkar D, Sarode SC, Sarode GS, Patil S, Sharma NK. CRISPR-Cas genome editing tool: A narrow lane of cancer therapeutics with potential blockades. Transl Cancer Res. 2020;9(4):3135–41.
47. Wu HY, Cao CY. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy. Brief Funct Genomics. 2019;18(2):129–32.
48. Hazafa A, Mumtaz M, Fras M, Bilal S, Nasir S, Firdous M, et al. CRISPR/Cas 9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions. Life Sci. 2020; 263: 118525.
49. Salas-Mckee J, Kong W, Gladney WL, Jadlowsky JK, Plesa G, Davis MM, et al. CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy. Hum Vaccines Immunother. 2019;15(5):1126–32. Disponible en: http://dx.doi.org/10.1080/21645515.2019.1571893
50. Mollanoori H, Shahraki H, Rahmati Y, Teimourian S. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. Hum Immunol. 2018;79(12):876–82. Disponible en: https://doi.org/10.1016/j.humimm.2018.09.007
51. Hu K jia, Yin ETS, Hu Y xian, Huang H. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies. Curr Med Sci. 2021;41(3):420–30.
52. Yang Y, Jacoby E, Fry TJ. Challenges and opportunities of allogeneic donorderived CAR T cells. Curr Opin Hematol. 2015;22(6):509–15.
53. Gao Q, Dong X, Xu Q, Zhu L, Wang F, Hou Y, et al. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy. Cancer Med. 2019;8(9):4254–64.
54. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545–53.
55. Robillard N, Wuillème S, Lodé L, Magrangeas F, Minvielle S, Avet-Loiseau H. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia. 2005;19(11):2021–2.
56. Jaskova K, Pavlovicova M, Jurkovicova D. Electrophysiological variability in the SH-SY5Y cellular line. Gen Physiol Biophys. 2014;31(4):375–82.
57. Xu Q, He S, Yu L. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis. Front Immunol. 2021;12:1-14.
58. Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo B, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;23(1):184–91.
59. Rafiq S, Purdon TJ, Schultz LM, Brentjens RJ. CD33-Directed Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML). Blood. 2016; 128(22):2825. Disponible en: https://doi.org/10.1182/blood.V128.22.2825.2825
60. Song D, Swartz MH, Biesecker SG, Borda F, Shah RR, Emtage P, et al. Chimeric Antigen Receptor-Modified T Cells for the Treatment of Acute Myeloid Leukemia Expressing CD33. Blood. 2016; 128(22):4058. Disponible en: https://doi.org/10.1182/blood.V128.22.4058.4058
61. O’Hear CE, Heiber J, Geiger TL. Anti-CD33 Chimeric Antigen Receptor Therapy For Acute Myeloid Leukemia. Blood . 2013;122(21):1441. Disponible en: https://doi.org/10.1182/blood.V122.21.1441.1441
62. Charrot S, Hallam S, Hallam CS. CAR-T Cells : Future Perspectives. Hemasphere. 2019; 3(2).
63. McHayleh W, Bedi P, Sehgal R, Solh M. Chimeric antigen receptor T-cells: The future is now. J Clin Med. 2019;8(2):3–5.
64. Miao L, Zhang Z, Ren Z, Li Y. Reactions Related to CAR-T Cell Therapy. Front Immunol. 2021;12(April).
65. Ruella M, Maus M V. Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. Comput Struct Biotechnol J . 2016;14:357–62. Disponible en; http://dx.doi.org/10.1016/j.csbj.2016.09.003
66. Xu J, Wang Y, Shi J, Liu J, Li Q, Chen L. Combination therapy: A feasibility strategy for car-t cell therapy in the treatment of solid tumors (review). Oncol Lett. 2018;16(2):2063–70.
67. Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS, et al. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. Cancer Cell. 2021;39(2):193-208.e10. Disponible en: https://doi.org/10.1016/j.ccell.2020.11.005